
PERSPECTIVES
Pharma commercial strategy
Independent perspectives from Kairos Meridian
Commercial strategy in pharma is not short of frameworks. It is short of clear choices. Brand plans grow to sixty slides, launch strategies try to say ten things at once, and the decisions that matter get made in whatever time is left.
These perspectives are about the discipline of choosing: what to stop, where to put the budget, how to build a go-to-market plan a team can actually run, and how to tell a story a prescriber, payer or buyer will remember.
Written from the practitioner’s seat, not the sidelines, by Kairos Meridian, an independent pharma commercial strategy consultancy with no platform to sell and no media to mark up.
ARTICLES

Omnichannel
October 14, 2026
Your Next Patient Has an Agent

Commercial Strategy
September 27, 2026
Stop Buying Hours. Start Buying a Mandate.

Direct-to-Patient (DTP)
August 30, 2026
It takes a village to launch a DTP program. It takes a group leading it to scale one.

Direct-to-Patient (DTP)
August 15, 2026
The DTP program launched. The channel didn't.

Direct-to-Patient (DTP)
July 30, 2026
The Real Value of Direct To Patient (DTP) For Pharma

Commercial Strategy
July 15, 2026
Simple is the new hard

Artificial Intelligence
June 30, 2026